AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
• Collaborator: Pfizer

Criteria

Inclusion Criteria:

• Diagnosis of probable AD

• Age from 50 to 85 years

• Rosen Modified Hachinski Ischemic score less than or equal to 4

• Magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD

• Fluency in English

• Stable doses of medications

Exclusion Criteria:

• Significant neurological disease other than AD

• Major psychiatric disorder

• Significant systemic illness

• History of stroke or seizure

• Weight greater than 120 kg (264 lbs.)

• History of autoimmune disease

• Smoking more than 20 cigarettes per day

• Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications

• Prior treatment with experimental immunotherapeutics or vaccines for AD

• Presence of pacemakers or foreign metal objects in the eyes, skin, or body